Francisco Real Group Leader
T +34 917328000 (Ext 3660)
freal@cnio.es

We focus on the molecular pathophysiology of pancreatic ductal adenocarcinoma (PDAC) and urothelial carcinoma (UC), with a disease-oriented approach. We use patient samples, cultured cells, and genetically modified mice, giving a similar weight to the 3 model systems. Primary observations made at either of these levels are then extended through additional work. To translate the findings, we bring this knowledge to a ‘population’ level, leveraging on information and samples from large patient cohorts.

In PDAC, a main hypothesis is that cell differentiation is a potent tumour suppressor mechanism acting early during carcinogenesis. We use the excellent genetic mouse models that are available because these processes cannot be readily studied using human samples. PDAC can originate both in pancreatic progenitors and in acinar cells. Understanding the contribution of early molecular events is crucial in order to design better strategies for early tumour detection and prevention in subjects at risk.

In UC, we focus on identifying new genes, using them for improved tumour taxonomy, characterising the mechanisms of action, and applying this knowledge for improved prediction of outcome and therapy.

Publications

• Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches(2019)
  Gomez-Rubio P, Piñero J, Molina-Montes E, Gutiérrez-Sacristán A, Marquez M, Rava M, Michalski CW, Farré A, Molero X, Löhr M, Perea J, Greenhalf W, O'Rorke M, Tardón A, Gress T, Barberá VM, Crnogorac-Jurcevic T, Muñoz-Bellvís L, Domínguez-Muñoz E, Balsells J, Costello E, Yu J, Iglesias M, Ilzarbe L, Kleeff J, Kong B, Mora J, Murray L, O'Driscoll D, Poves I, Lawlor RT, Ye W, Hidalgo M, Scarpa A, Sharp L, Carrato A, Real FX, Furlong LI, Malats N; PanGenEU Study Investigators
  Int J Cancer 144, 1540-1549.
• Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations(2019)
  Huang L, Jansen L, Balavarca Y, Molina-Montes E, Babaei M, van der Geest L, Lemmens V, Van Eycken L, De Schutter H, Johannesen TB, Fristrup CW, Mortensen MB, Žakelj MP, Zadnik V, Becker N, Hackert T, Magi M, Cassetti T, Sassatelli R, Grützmann R, Merkel S, Gonçalves AF, Bento MJ, Hegyi P, Lakatos G, Szentesi A, Moreau M, van de Velde T, Broeks A, Real FX, Carrato A, Molero X, Besselink MG, Malats N, Büchler MW, Schrotz-King P, Brenner H
  Gut 68, 130-139.
• Cdk4/6-inhibition induces bladder cancer regression independently of RB1 gene status(2019)
  Rubio R, Martínez-Fernández M, Segovia C, Lodewijk I, Suarez C, Segrelles C, López-Calderón F, Munera-Maravilla E, Santos M, Garcia-Escudero R, Lorz C, Gomez-Rodriguez MJ, de Velasco G, Otero Blas I, Villacampa F, Ruiz S, de la Rosa F, Domínguez-Rodríguez S, Real FX, Malats N, Castellano D, Dueñas M, Paramio J
  Clin Cancer Res 25, 390-402.
• Mouse Models Shed Light on the SLIT/ROBO Pathway in Pancreatic Development and Cancer(2019)
  Martinelli P, Real FX
  Trends in Cancer 5, 145-148.
• CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status(2019)
  Rubio C, Martínez-Fernández M, Segovia C, Lodewijk I, Suarez-Cabrera C, Segrelles C, López-Calderón F, Munera-Maravilla E, Santos M, Bernardini A, García-Escudero R, Lorz C, Gómez-Rodriguez MJ, de Velasco G, Otero I, Villacampa F, Guerrero-Ramos F, Ruiz S, de la Rosa F, Domínguez-Rodríguez S, Real FX, Malats N, Castellano D, Dueñas M, Paramio JM
  Clin Cancer Res 25, 390-402.
• Transcriptional regulation by NR5A2 links differentiation and inflammation in the pancreas(2018)
  Cobo I, Martinelli P, Flández M, Bakiri L, Zhang M, Carrillo-de-Santa-Pau E, Jia J, Sánchez-Arévalo Lobo VJ, Megías D, Felipe I, Del Pozo N, Millán I, Thommesen L, Bruland T, Olson SH, Smith J, Schoonjans K, Bamlet WR, Petersen GM, Malats N, Amundadottir LT, Wagner EF, Real FX
  Nature 554, 533-537.
• c-Myc downregulation is required for preacinar to acinar maturation and pancreatic homeostasis(2018)
  Sánchez-Arévalo Lobo VJ, Fernández LC, Carrillo-de-Santa-Pau E, Richart L, Cobo I, Cendrowski J, Moreno U, Del Pozo N, Megías D, Bréant B, Wright CV, Magnuson M, Real FX
  Gut 67, 707-718.
• Genetic unrelatedness of co-occurring pancreatic adenocarcinomas and IPMNs challenges current views of clinical management(2018)
  Scarpa A, Real FX, Luchini C
  Gut 67, 1561-1563.
• Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer(2018)
  Klein AP, Wolpin BM, Risch HA, Stolzenberg-Solomon RZ, Mocci E, Zhang M, Canzian F, Childs EJ, Hoskins JW, Jermusyk A, Zhong J, Chen F, Albanes D, Andreotti G, Arslan AA, Babic A, Bamlet WR, Beane-Freeman L, Berndt SI, Blackford A, Borges M, Borgida A, Bracci PM, Brais L, Brennan P, Brenner H, Bueno-de-Mesquita B, Buring J, Campa D, Capurso G, Cavestro GM, Chaffee KG, Chung CC, Cleary S, Cotterchio M, Dijk F, Duell EJ, Foretova L, Fuchs C, Funel N, Gallinger S, M Gaziano JM, Gazouli M, Giles GG, Giovannucci E, Goggins M, Goodman GE, Goodman PJ, Hackert T, Haiman C, Hartge P, Hasan M, Hegyi P, Helzlsouer KJ, Herman J, Holcatova I, Holly EA, Hoover R, Hung RJ, Jacobs EJ, Jamroziak K, Janout V, Kaaks R, Khaw KT, Klein EA, Kogevinas M, Kooperberg C, Kulke MH, Kupcinskas J, Kurtz RJ, Laheru D, Landi S, Lawlor RT, Lee IM, LeMarchand L, Lu L, Malats N, Mambrini A, Mannisto S, Milne RL, Mohelníková-Duchonová B, Neale RE, Neoptolemos JP, Oberg AL, Olson SH, Orlow I, Pasquali C, Patel AV, Peters U, Pezzilli R, Porta M, Real FX, Rothman N, Scelo G, Sesso HD, Severi G, Shu XO, Silverman D, Smith JP, Soucek P, Sund M, Talar-Wojnarowska R, Tavano F, Thornquist MD, Tobias GS, Van Den Eeden SK, Vashist Y, Visvanathan K, Vodicka P, Wactawski-Wende J, Wang Z, Wentzensen N, White E, Yu H, Yu K, Zeleniuch-Jacquotte A, Zheng W, Kraft P, Li D, Chanock S, Obazee O, Petersen GM, Amundadottir LT
  Nat Commun 9, 556-.
• Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma(2018)
  Alemany R, Moura DS, Redondo A, Martinez-Trufero J, Calabuig S, Saus C, Obrador-Hevia A, Ramos R, Villar VH, Valverde C, Vaz MA, Medina J, Felipe-Abrio I, Hindi N, Taron M, Martin-Broto J
  Clin Cancer Res 24, 5239-5249.
• CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status.(2018)
  Rubio C, Martínez-Fernández M, Segovia C, Lodewijk I, Suarez-Cabrera C, Segrelles C, López-Calderón F, Munera-Maravilla E, Santos M, Bernardini A, García-Escudero R, Lorz C, Gómez-Rodriguez MJ, de Velasco G, Otero I, Villacampa F, Guerrero-Ramos F, Ruiz S, de la Rosa F, Domínguez-Rodríguez S, Real FX, Malats N, Castellano D, Dueñas M, Paramio JM.
  Clin Cancer Res (in press).
• Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups(2018)
  van Kessel KEM, van der Keur KA, Dyrskjøt L, Algaba F, Welvaart NYC, Beukers W, Segersten U, Keck B, Maurer T, Simic T, Horstmann M, Grimm MO, Hermann GG, Mogensen K, Hartmann A, Harving N, Petersen AC, Jensen JB, Junker K, Boormans JL, Real FX, Malats N, Malmström PU, Ørntoft TF, Zwarthoff EC
  Clin Cancer Res 24, 1586-1593.
• Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives(2018)
  Molina-Montes E, Gomez-Rubio P, Márquez M, Rava M, Löhr M, Michalski CW, Molero X, Farré A, Perea J, Greenhalf W, Ilzarbe L, O'Rorke M, Tardón A, Gress T, Barberà VM, Crnogorac-Jurcevic T, Domínguez-Muñoz E, Muñoz-Bellvís L, Balsells J, Costello E, Huang J, Iglesias M, Kleeff J, Kong B, Mora J, Murray L, O'Driscoll D, Poves I, Scarpa A, Ye W, Hidalgo M, Sharp L, Carrato A, Real FX, Malats N; PanGenEU Study Investigators
  Int J Epidemiol 47, 473-483.
• Asthma status is associated with decreased risk of aggressive urothelial bladder cancer(2018)
  Rava M, Czachorowski MJ, Silverman D, Márquez M, Kishore S, Tardón A, Serra C, García-Closas M, Garcia-Closas R, Carrato A, Rothman N, Real FX, Kogevinas M, Malats N
  Int J Cancer 42, 470-476.
• GATA6 Controls Insulin Biosynthesis and Secretion in Adult ß-Cells(2018)
  Villamayor L, Rodríguez-Seguel E, Araujo R, Carrasco M, Bru-Tarí E, Mellado-Gil JM, Gauthier BR, Martinelli P, Quesada I, Soria B, Martín F, Cano DA, Rojas A
  Diabetes 67, 448-460.
• Mutant Kras Dosage and Chromothripsis: The Right Ingredients for a Pancreatic Cancer Catastrophe(2018)
  Real FX, de Andrés MP
  Trends in Cancer 4, 399-401.
• European evidence-based guidelines on pancreatic cystic neoplasms(2018)
  European Study Group on Cystic Tumours of the Pancreas
  Gut 67, 789-804.
• Agnostic pathway/gene set analysis of genome-wide association data identifies novel associations for pancreatic cancer(2018)
  Walsh N, Zhang H, Hyland PL, Yu K, Yang Q, … Real FX, …. Stolzenberg-Solomon, R
  J Natl Cancer I (in press).
• Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.(2017)
  Choi W, Ochoa A, McConkey DJ, Aine M, Höglund M, Kim WY, Real FX, Kiltie AE, Milsom I, Dyrskjøt L, Lerner SP.
  Eur Urol 72, 354-365.
• Prognostic impact of a 12-gene progression score in non-muscle invasive bladder cancer: a prospective multicenter validation study.(2017)
  Dyrskjøt L, Reinert T, Algaba F, Christensen E, Nieboer D, Hermann GG, Mogensen K, Marquez M, Segersten U, Høyer S, Ulhøi BP, Hartmann A, Stöhr R, Wach S, Nawroth R, Schwamborn K, Tulic K, Simic T, Junker K, Harving N, Petersen AC, Jensen JB, Keck B, Horstmann M, Maurer T, Steyerberg EW, Zwarthoff EC, Real EX, Malats N, Malmström PU, Ørntoft TF
  Eur Urol 72, 461-469.
• PIcKing on Fibroblast Growth Factor Receptors as Bladder Cancer Therapeutic Targets.(2017)
  Marqués M, Real FX.
  Eur Urol 17, 863-865.
• Reduced risk of pancreatic cancer associated with asthma and nasal allergies.(2017)
  Gómez-Rubio P, Zock JP, Rava M, Marquez M, Sharp L, Hidalgo M, Carrato A, Ilzarbe L, Michalski C, Molero X, Farré A, Perea J, Greenhalf W, O'Rorke M, Tardón A, Gress T, Barberà V, Crnogorac-Jurcevic T, Domínguez-Muñoz E, Muñoz-Bellvís L, Alvarez-Urturi C, Balcells J, Barneo L, Costello E, Guillén-Ponce C, Kleeff J, Kong B, Lawlor R, Löhr M, Mora J, Murray L, O'Driscoll D, Peláez P, Poves I, Scarpa A, Real FX, Malats N; PanGenEU Study Investigators
  Gut 66, 314-322.
• GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer.(2017)
  Martinelli P, Carrillo-de Santa Pau E, Cox T, Sainz B Jr, Dusetti N5 Greenhalf W, Rinaldi L, Costello E, Ghaneh P, Malats N, Büchler M, Pajic M, Biankin AV, Iovanna J, Neoptolemos J, Real FX.
  Gut 66, 1665-1676.
• A genetic roadmap of pancreatic cancer: still evolving.(2017)
  Notta F, Hahn SA, Real FX.
  Gut 66, 2170-2178.
• A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk.(2017)
  Gomez-Rubio P, Rosato V, Marquez M, Bosetti C, Molina-Montes E, Rava M, Piñero J, Michalski CW, Farré A, Molero X, Löhr M, Ilzarbe L, Perea J, Greenhalf W, O'Rorke M, Tardón A, Gress T, Barberà VM, Crnogorac-Jurcevic T, Muñoz-Bellvís L, Domínguez-Muñoz E, Gutiérrez-Sacristán A, Balsells J, Costello E, Guillén-Ponce C, Huang J, Iglesias M, Kleeff J, Kong B, Mora J, Murray L, O'Driscoll D, Peláez P, Poves I, Lawlor RT, Carrato A, Hidalgo M, Scarpa A, Sharp L, Furlong LI, Real FX, La Vecchia C, Malats N; PanGenEU Study Investigators.
  Ann Oncol 28, 1618-1624.
• Synthetic lethality between the cohesin subunits STAG1 and STAG2 in diverse cancer contexts.(2017)
  Van der Lelij P, Lieb S, Jude J, Witz G, Santos CP, Falkenberg K, Schlattl A, Ban J, Schwentner R, Kovar H, Real FX, Waldman T, Pearson M, Kraut N, Peters JM, Zuber J, Petronczki M
  Elife 6, e26980-.
• FGFR3, TERT and OTX1 as a urinary biomarker combination for surveillance of patients with bladder cancer in a large prospective multicenter study(2017)
  Beukers W, van der Keur KA, Kandimalla R, Vergouwe Y, Steyerberg EW, Boormans JL, Jensen JB, Lorente JA, Real FX, Segersten U, Orntoft TF, Malats N, Malmström PU, Dyrskjot L, Zwarthoff EC
  J Urology 197, 1410-1418.
• Validation of a DNA methylation-mutation urine assay to select patients with hematuria for cystoscopy.(2017)
  van Kessel KE, Beukers W, Lurkin I, Ziel-van der Made A, van der Keur KA, Boormans JL, Dyrskjøt L, Márquez M, Ørntoft TF, Real FX, Segersten U, Malats N, Malmström PU, Van Criekinge W, Zwarthoff EC
  J Urology 197, 590-595.
• BPTF is required for c-MYC transcriptional activity and in vivo tumorigenesis.(2016)
  Richart L, Carrillo-de Santa Pau E, Rio-Machin A, Pérez de Andrés M, Cigudosa JC, Sanchez-Arevalo Lobo VJ, Real FX
  Nat Communications 7, 10153-.
• The acinar regulator Gata6 suppresses KrasG12V-driven pancreatic tumorigenesis in mice.(2016)
  Martinelli P, Madriles F, Cañamero M, Pau EC, Pozo ND, Guerra C, Real FX.
  Gut 65, 476-486.
• A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns.(2016)
  Notta F, Chan-Seng-Yue M, Lemire M, Li Y, Wilson GW, Connor AA, Denroche RE, Liang SB, Brown AM, Kim JC, Wang T, Simpson JT, Beck T, Borgida A, Buchner N, Chadwick D, Hafezi-Bakhtiari S, Dick JE, Heisler L, Hollingsworth MA, Ibrahimov E, Jang GH, Johns J, Jorgensen LG, Law C, Ludkovski O, Lungu I, Ng K, Pasternack D, Petersen GM, Shlush LI, Timms L, Tsao MS, Wilson JM, Yung CK, Zogopoulos G, Bartlett JM, Alexandrov LB, Real FX, Cleary SP, Roehrl MH, McPherson JD, Stein LD, Hudson TJ, Campbell PJ, Gallinger S
  Nature 538, 378-382.
• Somatic mosaicism: on the road to cancer.(2016)
  Fernández LC, Torres M, Real FX.
  Nat Rev Cancer 16, 43-55.
• Mosaic loss of chromosome Y is associated with common variation near TCL1A.(2016)
  Zhou W, Machiela MJ, Freedman ND, Rothman N, Malats N, Dagnall C, Caporaso N, Teras LT, Gaudet MM, Gapstur SM, Stevens VL, Jacobs KB, Sampson J, Albanes D, Weinstein S, Virtamo J, Berndt S, Hoover RN, Black A, Silverman D, Figueroa J, Garcia-Closas M, Real FX, Earl J, Marenne G, Rodriguez-Santiago B, Karagas M, Johnson A, Schwenn M, Wu X, Gu J, Ye Y, Hutchinson A, Tucker M, Perez-Jurado LA, Dean M, Yeager M, Chanock SJ
  Nat Genet 48, 563-568.
• Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.(2016)
  Hedegaard J, Lamy P, Nordentoft I, Algaba F, Høyer S, Ulhøi BP, Vang S, Reinert T, Hermann GG, Mogensen K, Thomsen MB, Nielsen MM, Marquez M, Segersten U, Aine M, Höglund M, Birkenkamp-Demtröder K, Fristrup N, Borre M, Hartmann A, Stöhr R, Wach S, Keck B, Seitz AK, Nawroth R, Maurer T, Tulic C, Simic T, Junker K, Horstmann M, Harving N, Petersen AC, Calle ML, Steyerberg EW, Beukers W, van Kessel KE, Jensen JB, Pedersen JS, Malmström PU, Malats N, Real FX, Zwarthoff EC, Ørntoft TF, Dyrskjøt L
  Cancer Cell 30, 27-42.
• The N-Terminal Phosphorylation of RB by p38 Bypasses Its Inactivation by CDKs and Prevents Proliferation in Cancer Cells.(2016)
  Gubern A, Joaquin M, Marquès M, Maseres P, Garcia-Garcia J, Amat R, González-Nuñez D, Oliva B, Real FX, de Nadal E, Posas F
  Mol Cell 64, 25-36.
• Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome.(2016)
  Machiela MJ, Zhou W, Karlins E, Sampson JN, Freedman ND, Yang Q, Hicks B, Dagnall C, Hautman C, Jacobs KB, Abnet CC, Aldrich MC, Amos C, Amundadottir LT, Arslan AA, Beane-Freeman LE, Berndt SI, Black A, Blot WJ, Bock CH, Bracci PM, Brinton LA, Bueno-de-Mesquita HB, Burdett L, Buring JE, Butler MA, Canzian F, Carreón T, Chaffee KG, Chang IS, Chatterjee N, Chen C, Chen C, Chen K, Chung CC, Cook LS, Crous Bou M, Cullen M, Davis FG, De Vivo I, Ding T, Doherty J, Duell EJ, Epstein CG, Fan JH, Figueroa JD, Fraumeni JF, Friedenreich CM, Fuchs CS, Gallinger S, Gao YT, Gapstur SM, Garcia-Closas M, Gaudet MM, Gaziano JM, Giles GG, Gillanders EM, Giovannucci EL, Goldin L, Goldstein AM, Haiman CA, Hallmans G, Hankinson SE, Harris CC, Henriksson R, Holly EA, Hong YC, Hoover RN, Hsiung CA, Hu N, Hu W, Hunter DJ, Hutchinson A, Jenab M, Johansen C, Khaw KT, Kim HN, Kim YH, Kim YT, Klein AP, Klein R, Koh WP, Kolonel LN, Kooperberg C, Kraft P, Krogh V, Kurtz RC, LaCroix A, Lan Q, Landi MT, Marchand LL, Li D, Liang X, Liao LM, Lin D, Liu J, Lissowska J, Lu L, Magliocco AM, Malats N, Matsuo K, McNeill LH, McWilliams RR, Melin BS, Mirabello L, Moore L, Olson SH, Orlow I, Park JY, Patiño-Garcia A, Peplonska B, Peters U, Petersen GM, Pooler L, Prescott J, Prokunina-Olsson L, Purdue MP, Qiao YL, Rajaraman P, Real FX, Riboli E, Risch HA, Rodriguez-Santiago B, Ruder AM, Savage SA, Schumacher F, Schwartz AG, Schwartz KL, Seow A, Wendy Setiawan V, Severi G, Shen H, Sheng X, Shin MH, Shu XO, Silverman DT, Spitz MR, Stevens VL, Stolzenberg-Solomon R, Stram D, Tang ZZ, Taylor PR, Teras LR, Tobias GS, Van Den Berg D, Visvanathan K, Wacholder S, Wang JC, Wang Z, Wentzensen N, Wheeler W, White E, Wiencke JK, Wolpin BM, Wong MP, Wu C, Wu T, Wu X, Wu YL, Wunder JS, Xia L, Yang HP, Yang PC, Yu K, Zanetti KA, Zeleniuch-Jacquotte A, Zheng W, Zhou B, Ziegler RG, Perez-Jurado LA, Caporaso NE, Rothman N, Tucker M, Dean MC, Yeager M, Chanock SJ.
  Nat Communications 7, 11843-.
• The cis-regulatory switchboard of pancreatic ductal cancer.(2016)
  Ferrer J, Real FX
  EMBO J 35, 558-560.
• SPROUTY-2 represses the epithelial phenotype of colon carcinoma cells via upregulation of ZEB1 mediated by ETS1 and miR-200/miR-150.(2016)
  Barbachano A, Fernandez-Barral A, Pereira F, Segura MF, Ordonez-Moran P, Carrillo-de Santa Pau E, Gonzalez-Sancho JM, Hanniford D, Martinez N, Costales-Carrera A, Real FX, Palmer HG, Rojas JM, Hernando E, Munoz A
  Oncogene 35, 2991-3003.
• Somatic embryonic FGFR2 mutations in keratinocytic epidermal nevi.(2016)
  Toll A, Fernández LC, Pons T, Groesser L, Sagrera A, Carrillo-de Santa Pau E, Vicente A, Baselga E, Vázquez M, Beltrán S, Pisano DG, Rueda D, Gut M, Pujol RM, Hafner C, Gut I, Valencia A, Real FX
  J Invest Dermatol 136, 1718-1721.
• Choline Kinase Alpha (CHKa) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors.(2016)
  Mazarico JM, Sánchez-Arévalo Lobo VJ, Favicchio R, Greenhalf W, Costello E, Carrillo-de Santa Pau E, Marqués M, Lacal JC, Aboagye E, Real FX
  Mol Cancer Ther 15, 323-333.
• E-cadherin downregulation sensitizes PTEN mutant cells .(2016)
  Millán-Uclés A, Zuluaga S, Marqués M, Vallejo-Díaz J, Sanz L, Cariaga-Martínez AE, Real FX, Carrera AC
  Oncotarget 7, 84054-84071.
• Inflammatory-Related Genetic Variants in Non-Muscle-Invasive Bladder Cancer Prognosis: A Multimarker Bayesian Assessment.(2016)
  Masson-Lecomte A, López de Maturana E, Goddard ME, Picornell A, Rava M, González-Neira A, Márquez M, Carrato A, Tardon A, Lloreta J, Garcia-Closas M, Silverman D, Rothman N, Kogevinas M, Allory Y, Chanock SJ, Real FX, Malats N; SBC/EPICURO Study Investigators
  Cancer Epidem Biomar 25, 1144-1150.
• FGFR3, TERT and OTX1 as urinary biomarker combination for surveillance of bladder cancer patients in a large prospective multicenter study.(2016)
  Beukers W, van der Keur KA, Kandimalla R, Vergouwe Y, Steyerberg EW, Boormans JL, Jensen JB, Lorente JA, Real FX, Segersten U, Orntoft TF, Malats N, Malmström PU, Dyrskjot L, Zwarthoff EC
  J Urology (in press).
• Prediction of non-muscle invasive bladder cancer outcomes assessed by innovative multimarker prognostic models.(2016)
  López de Maturana E, Picornell A, Masson-Lecomte A, Kogevinas M, Márquez M, Carrato A, Tardón A, Lloreta J, García-Closas M, Silverman D, Rothman N, Chanock S, Real FX, Goddard ME, Malats N; SBC/EPICURO Study Investigators
  Bmc Cancer 16, 351-.
• International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer.(2016)
  Takaori K, Bassi C, Biankin A, Brunner TB, Cataldo I, Campbell F, Cunningham D, Falconi M, Frampton AE, Furuse J, Giovannini M, Jackson R, Nakamura A, Nealon W, Neoptolemos JP, Real FX, Scarpa A, Sclafani F, Windsor JA, Yamaguchi K, Wolfgang C, Johnson CD for the IPA/EPC study group on the clinical management of pancreatic cancer.
  Pancreatology 16, 14-27.
• Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting.(2016)
  Lerner SP, McConkey DJ, Hoadley KA, Chan KS, Kim WY, Radvanyi F, Höglund M, Real FX
  Bladder Cancer 2, 37-47.
• c-MYC partners with BPTF in human cancer.(2016)
  Richart L, Real FX, Sanchez-Arevalo Lobo VJ.
  Molecular Cellular Oncology 3, e1152346-.
• Mnk1 is a novel acinar cell-specific kinase required for exocrine pancreatic secretion and response to pancreatitis in mice.(2015)
  Cendrowski J, Sánchez-Arévalo Lobo VJ, Sendler M, Salas A, Kühn JP, Molero X, Fukunaga R, Mayerle J, Lerch MM, Real FX
  Gut 64, 937-947.
• Reduced risk of pancreatic cancer associated with asthma and nasal allergies.(2015)
  Gomez-Rubio P, Zock JP, Rava M, Marquez M, Sharp L, Hidalgo M, Carrato A, Ilzarbe L, Michalski C, Molero X, Farré A, Perea J, Greenhalf W, O'Rorke M, Tardón A, Gress T, Barberà V, Crnogorac-Jurcevic T, Domínguez-Muñoz E, Muñoz-Bellvís L, Alvarez-Urturi C, Balcells J, Barneo L, Costello E, Guillén-Ponce C, Kleeff J, Kong B, Lawlor R, Löhr M, Mora J, Murray L, O'Driscoll D, Peláez P, Poves I, Scarpa A, Real FX, Malats N; PanGenEU Study Investigators.
  Gut (in press).
• Intratumour Heterogeneity in Urologic Cancers: From Molecular Evidence to Clinical Implications.(2015)
  Gerlinger M, Catto JW, Orntoft TF, Real FX, Zwarthoff EC, Swanton C
  Eur Urol 67, 729-737.
• NOTCH pathway inactivation promotes bladder cancer progression.(2015)
  Maraver A, Fernandez-Marcos PJ, Cash TP, Mendez-Pertuz M, Dueñas M, Maietta P, Martinelli P, Muñoz-Martin M, Martínez-Fernández M, Cañamero M, Roncador G, Martinez-Torrecuadrada JL, Grivas D, de la Pompa JL, Valencia A, Paramio JM, Real FX, Serrano M
  J Clin Invest 125, 824-830.
• Modification of Occupational Exposures on Bladder Cancer Risk by Common Genetic Polymorphisms.(2015)
  Figueroa JD, Koutros S, Colt JS, Kogevinas M, Garcia-Closas M, Real FX, Friesen MC, Baris D, Stewart P, Schwenn M, Johnson A, Karagas MR, Armenti KR, Moore LE, Schned A, Lenz P, Prokunina-Olsson L, Banday AR, Paquin A, Ylaya K, Chung JY, Hewitt SM, Nickerson ML, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Malats N, Fraumeni JF Jr, Chanock SJ, Chatterjee N, Rothman N, Silverman DT
  J Natl Cancer I 107, djv223-.
• Characterization of large structural genetic mosaicism in human autosomes.(2015)
  Machiela MJ, Zhou W, Sampson JN, Dean MC, Jacobs KB, Black A, Brinton LA, Chang IS, Chen C, Chen C, Chen K, Cook LS, Crous Bou M, De Vivo I, Doherty J, Friedenreich CM, Gaudet MM, Haiman CA, Hankinson SE, Hartge P, Henderson BE, Hong YC, Hosgood HD 3rd, Hsiung CA, Hu W, Hunter DJ, Jessop L, Kim HN, Kim YH, Kim YT, Klein R, Kraft P, Lan Q, Lin D, Liu J, Le Marchand L, Liang X, Lissowska J, Lu L, Magliocco AM, Matsuo K, Olson SH, Orlow I, Park JY, Pooler L, Prescott J, Rastogi R, Risch HA, Schumacher F, Seow A, Setiawan VW, Shen H, Sheng X, Shin MH, Shu XO, VanDen Berg D, Wang JC, Wentzensen N, Wong MP, Wu C, Wu T, Wu YL, Xia L, Yang HP, Yang PC, Zheng W, Zhou B, Abnet CC, Albanes D, Aldrich MC, Amos C, Amundadottir LT, Berndt SI, Blot WJ, Bock CH, Bracci PM, Burdett L, Buring JE, Butler MA, Carreón T, Chatterjee N, Chung CC, Cook MB, Cullen M, Davis FG, Ding T, Duell EJ, Epstein CG, Fan JH, Figueroa JD, Fraumeni JF Jr, Freedman ND, Fuchs CS, Gao YT, Gapstur SM, Patiño-Garcia A, Garcia-Closas M, Gaziano JM, Giles GG, Gillanders EM, Giovannucci EL, Goldin L, Goldstein AM, Greene MH, Hallmans G, Harris CC, Henriksson R, Holly EA, Hoover RN, Hu N, Hutchinson A, Jenab M, Johansen C, Khaw KT, Koh WP, Kolonel LN, Kooperberg C, Krogh V, Kurtz RC, LaCroix A, Landgren A, Landi MT, Li D, Liao LM, Malats N, McGlynn KA, McNeill LH, McWilliams RR, Melin BS, Mirabello L, Peplonska B, Peters U, Petersen GM, Prokunina-Olsson L, Purdue M, Qiao YL, Rabe KG, Rajaraman P, Real FX, Riboli E, Rodríguez-Santiago B, Rothman N, Ruder AM, Savage SA, Schwartz AG, Schwartz KL, Sesso HD, Severi G, Silverman DT, Spitz MR, Stevens VL, Stolzenberg-Solomon R, Stram D, Tang ZZ, Taylor PR, Teras LR, Tobias GS, Viswanathan K, Wacholder S, Wang Z, Weinstein SJ, Wheeler W, White E, Wiencke JK, Wolpin BM, Wu X, Wunder JS, Yu K, Zanetti KA, Zeleniuch-Jacquotte A, Ziegler RG, de Andrade M, Barnes KC, Beaty TH, Bierut LJ, Desch KC, Doheny KF, Feenstra B, Ginsburg D, Heit JA, Kang JH, Laurie CA, Li JZ, Lowe WL, Marazita ML, Melbye M, Mirel DB, Murray JC, Nelson SC, Pasquale LR, Rice K, Wiggs JL, Wise A, Tucker M, Pérez-Jurado LA, Laurie CC, Caporaso NE, Yeager M, Chanock SJ.
  Am J Hum Genet 96, 487-497.
• Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma.(2015)
  Radon TP, Massat NJ, Jones R, Alrawashdeh W, Dumartin L, Ennis D, Duffy SW, Kocher HM, Pereira SP, Guarner Posthumous L, Murta-Nascimento C, Real FX, Malats N, Neoptolemos J, Costello E, Greenhalf W, Lemoine NR, Crnogorac-Jurcevic T.
  Clin Cancer Res 21, 3512-3521.
• AID-expressing epithelium is protected from oncogenic transformation by an NKG2D surveillance pathway.(2015)
  Pérez-García A, Pérez-Durán P, Wossning T, Sernandez IV, Mur SM, Cañamero M, Real FX, Ramiro AR
  EMBO Mol Med 7, 1327-1336.
• Integration Analysis of Three Omics Data Using Penalized Regression Methods: An Application to Bladder Cancer.(2015)
  Pineda S, Real FX, Kogevinas M, Carrato A, Chanock S, Malats N*, Van Steen K*
  PLoS Genet 11, e1005689-.
• PanGen-Fam: Spanish registry of hereditary pancreatic cancer.(2015)
  Mocci E, Guillen-Ponce C, Earl J, Marquez M, Solera J, Salazar-López MT, Calcedo-Arnáiz C, Vázquez-Sequeiros E, Montans J, Muñoz-Beltrán M, Vicente-Bártulos A, González-Gordaliza C, Sanjuanbenito A, Guerrero C, Mendía E, Lisa E, Lobo E, Martínez JC, Real FX, Malats N, Carrato A.
  Eur J Cancer 51, 1911-1917.
• PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.(2015)
  Dueñas M, Martínez-Fernández M, García-Escudero R, Villacampa F, Marqués M, Saiz-Ladera C, Duarte J, Martínez V, Gómez MJ, Martín ML, Fernández M, Castellano D, Real FX, Rodriguez-Peralto JL, De La Rosa F, Paramio JM
  Mol Carcinogen 54, 566-576.
• The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.(2015)
  Earl J, Rico D, Carrillo-de-Santa-Pau E, Rodríguez-Santiago B, Méndez-Pertuz M, Auer H, Gómez G, Grossman HB, Pisano DG, Schulz WA, Pérez-Jurado LA, Carrato A, Theodorescu D, Chanock S, Valencia A, Real FX.
  Bmc Genomics 16, 403-.
• Addressing the challenges of pancreatic cancer: future directions for improving outcomes.(2015)
  Hidalgo M, Cascinu S, Kleeff J, Labianca R, Löhr JM, Neoptolemos J, Real FX, Van Laethem JL, Heinemann V.
  Pancreatology 15, 8-18.
• Epidemiology of bladder cancer.(2015)
  Malats N, Real FX
  Hematol Oncol Clin N 29, 177-189.
• Framework for the Integration of Genomics, Epigenomics and Transcriptomics in Complex Diseases.(2015)
  Pineda S, Gomez-Rubio P, Picornell A, Bessonov K, Márquez M, Kogevinas M, Real FX, Van Steen K, Malats N
  Hum Hered 79, 124-136.
• A Multicenter Trial Defining a Serum Protein Signature Associated with Pancreatic Ductal Adenocarcinoma.(2015)
  Gerdtsson AS, Malats N, Säll A, Real FX, Porta M, Skoog P, Persson H, Wingren C, Borrebaeck CA
  Int J Proteomics 2015, 587250-.
• Nicotine Promotes Initiation and Progression of KRAS-Induced Pancreatic Cancer via Gata6-Dependent Dedifferentiation of Acinar Cells in Mice.(2014)
  Hermann PC, Sancho P, Cañamero M, Martinelli P, Madriles F, Michl P, Gress T, de Pascual R, Gandia L, Guerra C, Barbacid M, Wagner M, Vieira CR, Aicher A, Real FX, Sainz B Jr, Heeschen C
  Gastroenterology 147, 1119-1133.
• Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer.(2014)
  Wolpin BM, Rizzato C, Kraft P, Kooperberg C, Petersen GM, Wang Z, Arslan AA, Beane-Freeman L, Bracci PM, Buring J, Canzian F, Duell EJ, Gallinger S, Giles GG, Goodman GE, Goodman PJ, Jacobs EJ, Kamineni A, Klein AP, Kolonel LN, Kulke MH, Li D, Malats N, Olson SH, Risch HA, Sesso HD, Visvanathan K, White E, Zheng W, Abnet CC, Albanes D, Andreotti G, Austin MA, Barfield R, Basso D, Berndt SI, Boutron-Ruault MC, Brotzman M, Büchler MW, Bueno-de-Mesquita HB, Bugert P, Burdette L, Campa D, Caporaso NE, Capurso G, Chung C, Cotterchio M, Costello E, Elena J, Funel N, Gaziano JM, Giese NA, Giovannucci EL, Goggins M, Gorman MJ, Gross M, Haiman CA, Hassan M, Helzlsouer KJ, Henderson BE, Holly EA, Hu N, Hunter DJ, Innocenti F, Jenab M, Kaaks R, Key TJ, Khaw KT, Klein EA, Kogevinas M, Krogh V, Kupcinskas J, Kurtz RC, LaCroix A, Landi MT, Landi S, Le Marchand L, Mambrini A, Mannisto S, Milne RL, Nakamura Y, Oberg AL, Owzar K, Patel AV, Peeters PH, Peters U, Pezzilli R, Piepoli A, Porta M, Real FX, Riboli E, Rothman N, Scarpa A, Shu XO, Silverman DT, Soucek P, Sund M, Talar-Wojnarowska R, Taylor PR, Theodoropoulos GE, Thornquist M, Tjønneland A, Tobias GS, Trichopoulos D, Vodicka P, Wactawski-Wende J, Wentzensen N, Wu C, Yu H, Yu K, Zeleniuch-Jacquotte A, Hoover R, Hartge P, Fuchs C, Chanock SJ, Stolzenberg-Solomon RS, Amundadottir LT
  Nat Genet 46, 994-1000.
• The transcription factor GATA6 enables self-renewal of colon adenoma stem cells by repressing BMP gene expression.(2014)
  Whissell G, Montagni E, Martinelli P, Hernando-Momblona X, Sevillano M, Jung P, Cortina C, Calon A, Abuli A, Castells A, Castellvi-Bel S, Nacht AS, Sancho E, Stephan-Otto Attolini C, Vicent GP, Real FX, Batlle E.
  Nat Cell Biol 16, 695-707.
• Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.(2014)
  Barceló C, Etchin J, Mansour MR, Sanda T, Ginesta MM, Sanchez-Arévalo Lobo VJ, Real FX, Capellà G, Estanyol JM, Jaumot M, Look AT, Agell N
  Gastroenterology 147, 882-892.
• Polymorphisms at PRSS1-PRSS2 and CLDN2-MORC4 loci associate with alcoholic and non-alcoholic chronic pancreatitis in a European replication study.(2014)
  Derikx MH, Kovacs P, Scholz M, Masson E, Chen JM, Ruffert C, Lichtner P, Te Morsche RH, Cavestro GM; PanEuropean Working group on Alcoholic Chronic Pancreatitis members and collaborators, Férec C, Drenth JP, Witt H, Rosendahl J, Algül H, Berg T, Bödeker H, Blüher M, Bruno MJ, Buch S, Bugert P, Cichoz-Lach H, Dabrowski A, Farré A, Frank J, Gasiorowska A, Geisz A, Goni E, Grothaus J, Grützmann R, Haas S, Hampe J, Hellerbrand C, Hegyi P, Huster D, Ioana M, Iordache S, Jurkowska G, Keim V, Landt O, Di Leo M, Lerch MM, Lévy P, Löhr MJ, Macek M, Malats N, Malecka-Panas E, Mariani A, Martorana D, Mayerle J, Mora J, Mössner J, Müller S, Ockenga J, Paderova J, Pedrazzoli S, Pereira SP, Pfützer R, Real FX, Rebours V, Ridinger M, Rietschel M, Rohde K, Sack S, Saftoiu A, Schneider A, Schulz HU, Soyka M, Simon P, Skipworth J, Stickel F, Stumvoll M, Testoni PA, Tönjes A, Treiber M, Weiss FU, Werner J, Wodarz N
  Gut (in press).
• Nr5a2 heterozygosity sensitises to, and cooperates with, inflammation in KRasG12V-driven pancreatic tumourigenesis.(2014)
  Flandez M, Cendrowski J, Cañamero M, Salas A, Del Pozo N, Schoonjans K, Real FX
  Gut 63, 647-655.
• Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.(2014)
  Allory Y, Beukers W, Sagrera A, Flandez M, Marques M, Marquez M, van der Keur A, Dyrskjot L, Lurkin I, Vermej M, Carrato A, Lloreta J, Lorente JA, Carrillo-de-Santa-Pau E, Masius RG, Kogevinas M, Steyerberg EW, van Tilborg AAG, Abas C, Orntoft TF, Zuiverloon TCM, Malats N, Zwarthoff EC, Real FX
  Eur Urol 65, 360-366.
• Inflammatory Biomarkers and Bladder Cancer Prognosis: A Systematic Review.(2014)
  Masson-Lecomte A, Rava M, Real FX, Hartmann A, Allory Y, Malats N
  Eur Urol 66, 1078-1091.
• Next-generation Sequencing of Urologic Cancers: Next Is Now.(2014)
  Real FX, Boutros PC, Malats N
  Eur Urol 66, 4-7.
• Klf4 and Klf5 differentially inhibit mesoderm and endoderm differentiation in embryonic stem cells.(2014)
  Aksoy I, Giudice V, Delahaye E, Wianny F, Aubry M, Mure M, Chen J, Jauch R, Bogu GK, Nolden T, Himmelbauer H, Xavier Doss M, Sachinidis A, Schulz H, Hummel O, Martinelli P, Hübner N, Stanton LW, Real FX, Bourillot PY, Savatier P
  Nat Communications 5, 3719-.
• Transcriptome analysis of pancreatic cancer reveals a tumor suppressor function for HNF1A.(2014)
  Hoskins JW, Jia J, Flandez M, Parikh H, Xiao W, Collins I, Emmanuel MA, Ibrahim A, Powell J, Zhang L, Malats N, Bamlet WR, Peterson GM, Real FX, Amundadottir LT
  Carcinogenesis 35, 2670-2678.
• LINE-1 methylation in leukocyte DNA, interaction with phosphatidylethanolamine N-methyltransferase variants and bladder cancer risk.(2014)
  Tajuddin SM, Amaral AF, Fernández AF, Chanock S, Silverman DT, Tardón A, Carrato A, García-Closas M, Jackson BP, Toraño EG, Márquez M, Urdinguio RG, García-Closas R, Rothman N, Kogevinas M, Real FX1, Fraga MF, Malats N; Spanish Bladder Cancer/EPICURO Study investigators.
  Br J Cancer 110, 2123-2130.
• LINE-1 methylation in granulocyte DNA and trihalomethane exposure is associated with bladder cancer risk.(2014)
  Salas LA, Villanueva CM, Tajuddin SM, Amaral AF, Fernandez AF, Moore LE, Carrato A, Tardón A, Serra C, García-Closas R, Basagaña X, Rothman N, Silverman DT, Cantor KP, Kogevinas M, Real FX, Fraga MF, Malats N
  Epigenetics 9, 1532-1539.
• PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases.(2014)
  Martín-Sánchez E, Odqvist L, Rodríguez-Pinilla SM, Sánchez-Beato M, Roncador G, Domínguez-González B, Blanco-Aparicio C, García Collazo AM, Cantalapiedra EG, Fernández JP, Curiel del Olmo S, Pisonero H, Madureira R, Almaraz C, Mollejo M, Alves FJ, Menárguez J, González-Palacios F, Rodríguez-Peralto JL, Ortiz-Romero PL, Real FX, García JF, Bischoff JR, Piris MA
  PLoS ONE 9, e1121148-.
• Genetic Variation in the TP53 Pathway and Bladder Cancer Risk. A Comprehensive Analysis.(2014)
  Pineda S, Milne RL, Calle ML, Rothman N, López de Maturana E, Herranz J, Kogevinas M, Chanock SJ, Tardón A, Márquez M, Guey LT, García-Closas M, Lloreta J, Baum E, González-Neira A, Carrato A, Navarro A, Silverman DT, Real FX, Malats N
  PLoS ONE 9, e89952.-.
• Risk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: an international validation in primary tumours.(2014)
  Vedder MM, Márquez M, de Bekker-Grob EW, Calle ML, Dyrskjøt L, Kogevinas M, Segersten U, Malmström PU, Algaba F, Beukers W, Orntoft TF, Zwarthoff E, Real FX, Malats N, Steyerberg EW
  PLoS ONE 9, e96849-.
• Whole Genome Prediction of Bladder Cancer Risk With the Bayesian LASSO.(2014)
  López de Maturana E, Chanok SJ, Picornell AC, Rothman N, Herranz J, Calle ML, García-Closas M, Marenne G, Brand A, Tardón A, Carrato A, Silverman DT, Kogevinas M, Gianola D, Real FX, Malats N
  Genet Epidemiol 38, 467-476.
• Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy.(2013)
  Balbás-Martínez C, Sagrera A, Carrillo-de-Santa-Pau E, Earl J, Márquez M, Vazquez M, Lapi E, Castro-Giner F, Beltran S, Bayés M, Carrato A, Cigudosa JC, Domínguez O, Gut M, Herranz J, Juanpere N, Kogevinas M, Langa X, López-Knowles E, Lorente JA, Lloreta J, Pisano DG, Richart L, Rico D, Salgado RN, Tardón A, Chanock S, Heath S, Valencia A, Losada A, Gut I, Malats N, Real FX
  Nat Genet 45, 1464-1469.
• Gata6 is required for complete acinar differentiation and maintenance of the exocrine pancreas in adult mice.(2013)
  Martinelli P, Cañamero M, del Pozo N, Madriles F, Zapata A, Real FX
  Gut 62, 1481-1488.
• Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer.(2013)
  Garcia-Closas M, Rothman N, Figueroa JD, Prokunina-Olsson L, Han SS, Baris D, Jacobs EJ, Malats N, De Vivo I, Albanes D, Purdue MP, Sharma S, Fu YP, Kogevinas M, Wang Z, Tang W, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Andriole G Jr, Grubb R 3rd, Black A, Gapstur SM, Thun M, Diver WR, Weinstein SJ, Virtamo J, Hunter DJ, Caporaso N, Landi MT, Hutchinson A, Burdett L, Jacobs KB, Yeager M, Fraumeni JF Jr, Chanock SJ, Silverman DT, Chatterjee N.
  Cancer Res 73, 2211-2220.
• Sirtuin-1 Regulates Acinar-to-Ductal Metaplasia and Supports Cancer Cell Viability in Pancreatic Cancer.(2013)
  Wauters E, Sanchez-Arévalo Lobo VJ, Pinho AV, Mawson A, Herranz D, Wu J, Cowley MJ, Colvin EK, Njicop EN, Sutherland RL, Liu T, Serrano M, Bouwens L, Real FX, Biankin AV, Rooman I
  Cancer Res 73, 2357-2367.
• Genetic and Non-genetic Predictors of LINE-1 Methylation in Leukocyte DNA.(2013)
  Tajuddin SM, Amaral AF, Fernández AF, Rodríguez-Rodero S, Rodríguez RM, Moore LE, Tardón A, Carrato A, García-Closas M, Silverman DT, Jackson BP, García-Closas R, Cook AL, Cantor KP, Chanock S, Kogevinas M, Rothman N, Real FX, Fraga MF, Malats N
  Environ Health Persp 121, 650-656.
• Phacomatosis pigmentokeratotica is caused by a postzygotic HRAS mutation in a multipotent progenitor cell.(2013)
  Groesser L, Herschberger E, Sagrera A, Shwayder T, Flux K, Ehmann L, Wollenberg A, Torrelo A, Bagazgoitia L, Diaz-Ley B, Tinschert S, Oschlies I, Singer S, Mickler M, Toll A, Landthaler M, Real FX, Hafner C.
  J Invest Dermatol 133, 1998-2003.
• Bladder cancer and seroreactivity to BK, JC and Merkel cell polyomaviruses: The Spanish bladder cancer study.(2013)
  Robles C, Viscidi R, Malats N, Silverman DT, Tardon A, Garcia-Closas R, Serra C, Carrato A, Herranz J, Lloreta J, Rothman N, Real FX, de Sanjose S, Kogevinas M
  Int J Cancer 133, 597-603.
• ICAT is a novel Ptf1a interactor that regulates pancreatic acinar differentiation and displays altered expression in tumours.(2013)
  Campos ML, Sánchez-Arévalo Lobo VJ, Rodolosse A, Gottardi CJ, Mafficini A, Beghelli S, Scardoni M, Bassi C, Scarpa A, Real FX
  Biochem J 451, 395-405.
• ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors.(2013)
  Balbás-Martínez C, Rodríguez-Pinilla M, Casanova A, Domínguez O, Pisano DG, Gómez G, Lloreta J, Lorente JA, Malats N, Real FX
  PLoS ONE 8, e62483-.
• Application of multi-SNP approaches Bayesian LASSO and AUC-RF to detect main effects of inflammatory-gene variants associated with bladder cancer risk.(2013)
  de Maturana EL, Ye Y, Calle ML, Rothman N, Urrea V, Kogevinas M, Petrus S, Chanock SJ, Tardón A, García-Closas M, González-Neira A, Vellalta G, Carrato A, Navarro A, Lorente-Galdós B, Silverman DT, Real FX, Wu X, Malats N
  PLoS ONE 8, e83745-.
• EU Pancreas: An Integrated European Platform for Pancreas Cancer Research – from Basic Science to Clinical and Public Health Interventions for a Rare Disease.(2013)
  Milne R, La Vecchia C, Van Steen K, Hahn S, Buchholz M, Costello E, Esposito I, Hoheisel JD, Lange B, Lopez-Bigas N, Michalski CW, Real FX, Brand A, Malats N
  Public Health Genomics 16, 305-312.
• Many mosaic mutations.(2013)
  Foulkes WD, Real FX
  Curr Oncol 20, 85-87.